Zhong Lun advised LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm. LaNova Medicines Technology (Shanghai)...
Zhong Lun advised LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm. LaNova Medicines Technology (Shanghai)...
You must be a Standard 1 Year member to access this content.